A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer

Familial Cancer

Volumn 11, Issue 3, 2012, Pages 419-427

  Engel, Natalie J ^a   Gordon, Patricia ^b   Thull, Darcy L ^a   Dudley, Beth ^a   Herstine, Judy ^b   Jankowitz, Rachel C ^b   Zorn, Kristin K ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

BRCA1 mutation; BRCA2 mutation; Cancer risk management; Hereditary breast and ovarian cancer syndrome; Multidisciplinary clinic

Indexed keywords

AROMATASE INHIBITOR; CA 125 ANTIGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; BRCA GENE; BREAST CANCER; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; FAMILIAL CANCER; GENE MUTATION; GENETIC COUNSELING; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVARY CANCER; PATIENT COUNSELING; PATIENT PREFERENCE; PATIENT SATISFACTION; PERSONALIZED MEDICINE; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY;

AGE FACTORS; BREAST NEOPLASMS; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; OUTPATIENT CLINICS, HOSPITAL; OVARIAN NEOPLASMS; PENNSYLVANIA; RISK FACTORS;

EID: 84870453484     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-012-9530-x     Document Type: Article

References (37)

1. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988):1684-1689
2. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D et al (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265(5181):2088-2090
3. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343(8899):692-695
4. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20): 1401-1408
5. Whittemore AS, Gong G, Itnyre J (1997) Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 60(3):496-504
6. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62(3):676-689
7. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329-1333
8. American Cancer Society (2012) Cancer facts and figures. Available online at http://cancer.org
9. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12):1379-1388
10. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165-167
11. Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC (2011) Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 71(6):2222-2229
12. Lynch HT, Snyder C, Lynch J (2012) Hereditary breast cancer: practical pursuit for clinical translation. Ann Surg Oncol 19(6):1723-1731
13. Cusack JC Jr., Hughes KS (2012) Managing patients at high risk for hereditary breast cancer: a guide for the practicing physician. Ann Surg Oncol 19(6):1721-1722
14. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, Swisher EM (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108(44):18032-18037
15. Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11(2):103-105
16. Pennington KP, Swisher EM (2012) Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol 124(2):347-353
17. Network NC (2011) Genetic/familial high risk assessment: breast and ovarian. vol 1. NCCN, available online at http://NCCN.org
18. Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L, Freedman AN (2005) Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet 42(10):749-755
19. McKinnon W, Naud S, Ashikaga T, Colletti R, Wood M (2007) Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing. J Genet Couns 16(4):433-456
20. Karp J, Brown K, Sullivan MD, Massie MJ (1999) The prophylactic mastectomy dilemma: A support group for women at high genetic risk for breast cancer. J Genet Couns 8(3):163-173
21. Esplen MJ, Hunter J, Leszcz M, Warner E, Narod S, Metcalfe K, Glendon G, Butler K, Liede A, Young MA, Kieffer S, DiProspero L, Irwin E, Wong J (2004) A multicenter study of supportiveexpressive group therapy for women with BRCA1/BRCA2 mutations. Cancer 101
22. Bancroft EK, Locke I, Ardern-Jones A, D'Mello L, McReynolds K, Lennard F, Barbachano Y, Barwell J, Walker L, Mitchell G, Dorkins H, Cummings C, Paterson J, Kote-Jarai Z, Mitra A, Jhavar S, Thomas S, Houlston R, Shanley S, Eeles RA (2010) The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers-implications for oncogenetics practice. J Med Genet 47(7):486-491
23. Antill YC, Shanahan M, Phillips K (2005) The integrated, multidisciplinary clinic: a new model for the ongoing management of women at high genetic risk for breast and ovarian cancer. Cancer Forum 29(2):107-110
24. Kuschel B, Lux MP, Goecke TO, Beckmann MW (2000) Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Eur J Cancer Prev 9(3):139-150
25. Hilgart JS, Coles B, Iredale R (2012) Cancer genetic risk assessment for individuals at risk of familial breast cancer. Cochrane Database Syst Rev 2:CD003721
26. Ardern-Jones A, Eeles RA (2004) Development in clinical practice: follow up clinic for BRCA mutation carriers: a case study highlighting the "virtual clinic". Hered Cancer Clin Pract 2:77-79
27. Pichert G, Jacobs C, Jacobs I, Menon U, Manchanda R, Johnson M, Hamed H, Firth C, Evison M, Tutt A, de Silva L, Langman C, Izatt L (2010) Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. Fam Cancer 9(3):313-319
28. Firth C, Jacobs C, Evison M, Pichert G, Izatt L, Hunter MS (2011) Novel one-stop multidisciplinary follow-up clinic for BRCA1/2 carriers: patient satisfaction and decision making. Psycho-oncology 20(12):1301-1308
29. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H (2011) Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12(5):496-503
30. Ravdin PM (2010) The lack, need, and opportunities for decisionmaking and informational tools to educate primary-care physicians and women about breast cancer chemoprevention. Cancer Prev Res (Phila) 3(6):686-688
31. Kaplan CP, Haas JS, Perez-Stable EJ, Des Jarlais G, Gregorich SE (2005) Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 41(1):7-15
32. Sabatino SA, McCarthy EP, Phillips RS, Burns RB (2007) Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers. Cancer Detect Prev 31(5): 375-383
33. Cuzick J (2009) Use of selective estrogen receptor modulators in the prevention of breast cancer: an overview of the randomized trials. Cancer Res 69 (24 Supp):Abstract 905
34. U.T. Southwestern Medical Center Group. CancerGene (2012) Available online at www4.utsouthwestern.edu/breasthealth/cagene
35. Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, Anderson GL, McCaskill-Stevens W (2011) Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 29(17):2327-2333
36. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75-89
37. Rungruang B, Hood BL, Sun M, Hoskins E, Conrads TP, Zorn KK (2010) Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome. J Proteome Res 9(11):6071-6076